MOTS-c in Humans: What Evidence Actually Exists

Endogenous measurement studies

People make MOTS-c. That fact is the starting point of the human evidence, not its close. A laboratory can draw blood or tissue and quantify the natural peptide. That is endogenous measurement.^1,2

This page inventories so that “human study” is not read as “treatment trial.” The general map is in the MOTS-c hub.

Evidence inflation starts with a vague label. “Human” can mean a cell derived from a person, a blood draw, a cohort, or a trial that administers the peptide. Those four things do not weigh the same. Here they are named separately.

Exercise studies

Exercise is the intervention in several human papers. Participants ran, used a bicycle, or completed an endurance protocol. Endogenous MOTS-c — and sometimes humanin — was measured before and after.^1,2

That can show that the natural peptide moves with effort. It does not show what happens if synthetic MOTS-c is given. The exercise page develops that distinction.¹

Reynolds 2021 includes human observation and, in the same publication, mouse administration. The human half does not turn the animal half into a clinical trial.²

Observational cohorts

Other lines measure circulating MOTS-c in metabolism, aging, kidney-disease, or other association cohorts. One current example is a 2024 multicenter hemodialysis study with 94 patients.³

Association is not treatment. A cohort can inform a hypothesis. It does not replace a randomized administration trial.

Other aging, sleep, or metabolism cohorts can enter the same class if they only measure the natural peptide. The criterion is not the clinical topic. The criterion is whether someone administered MOTS-c or only quantified it.

Administered MOTS-c

The human-administration layer identified in this system is NCT07505745, MOTS-MET. It is Phase 2a, randomized, double-blind, and placebo-controlled. The status reviewed on 1 September 2026 is Recruiting. No results are posted.⁵

FDA’s July 2026 briefing could accurately state that human data from products containing MOTS-c-related bulk substances were lacking. A 2026 registry record does not erase that reading: the registry has not posted results.^6,5

Counting “a human trial” because NCT07505745 exists is, today, counting a protocol. The protocol matters. It does not replace an outcome read by peers or posted on the registry.

Until that outcome exists, the honest human inventory is: endogenous measurement, exercise physiology, observational cohorts, and one recruiting administration study with no posted results.

Do not inflate the evidence

• Do not count fibroblasts, cells, or mice as human evidence.⁴
• Do not count an endogenous measurement as a treatment trial.¹
• Do not count a biomarker cohort as therapeutic efficacy.³
• Do not count NCT07505745 as a clinical result.⁵
• Completed human administration trials with posted results: none identified in this 1 September 2026 review.

The metabolic line is in metabolism and insulin. Exercise is in human measurements versus mice.